Day: June 3, 2025

VANCOUVER, British Columbia, June 03, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announces that it is pushing forward on drone swarms, US military applications, and quantum computing projects that it will highlight at three upcoming investor conferences this week. “Drones are playing an increasingly vital role in modern military warfare, as world events continue to remind us,” said Shaun Passley, Ph.D., CEO of ZenaTech. “Success on the battlefield is no longer reliant on brute force or firepower—it’s about intelligent, networked systems that deliver speed, data, and autonomy.” These investor conferences are attended...

The order marks a significant commercial milestone and signals Rail Vision’s continued expansion in the Latin American market Ra’anana, Israel, June 03, 2025 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN), a leader in railway safety and AI-driven vision technology, announced today it has secured a $335,000 follow-on order from a prominent Latin American mining company for its MainLine system. The order follows a long-term and successful trial of the system under demanding operational and environmental conditions. This order reinforces Rail Vision’s increasing commercial traction in Latin America and marks an important step in expanding the client’s deployment of MainLine across its railway fleet. The system will play a critical role in enhancing safety and optimizing rail transport efficiency within the mining company’s extensive...

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the “Pool 1 Notes”); USD 4.750% Sustainability-Linked Senior Notes due 2027, CUSIP 88167AAP6 / ISIN US88167AAP66 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the “Priority 2 Notes”); EUR 3.750% Sustainability-Linked Senior Notes due 2027, Common Code 240660709 / ISIN XS2406607098 (Registered), issued by Teva Pharmaceutical...

Tampa, Florida, June 03, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce the first deliveries of its revolutionary Flex FPV (First Person View) systems under an order from a major U.S. military prime contractor supporting land systems operations for allied forces. The Draganfly Flex FPV system is built around a modular core architecture that allows operators to seamlessly switch between different arm and propeller sizes in seconds—without specialized tools. This adaptability enables a single Flex Core to support a variety of mission profiles ranging from reconnaissance and training to tactical payload delivery. Capable of speeds exceeding 149 Kilometres per hour, the Flex FPV is designed to support traditional...

Cloud architecture and 5G-NTN future readiness included in this platform define the next phase of Gilat’s ground segment innovation PETAH TIKVA, Israel, June 03, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that it has received a $40 million contract for its virtualized SkyEdge IV platform, expected to be delivered over the next 24 months. Designed with a cloud-native architecture and ready for future 5G-NTN (Non-Terrestrial Network) standards, the platform marks a major step forward in the transformation of satellite ground networks, enabling satellite operators and service providers to meet the evolving demands of modern connectivity. This milestone award demonstrates the successful evolution strategy...

WEST PALM BEACH, Fla., June 03, 2025 (GLOBE NEWSWIRE) — AMG, a strategic partner to leading independent investment management firms globally, today announced the appointment of Thomas M. Wojcik as President, effective June 3, 2025. Mr. Wojcik will also continue to serve as Chief Operating Officer. Jay C. Horgen, previously President and Chief Executive Officer, will continue as Chief Executive Officer. In his expanded role, Mr. Wojcik will continue to work with Mr. Horgen on developing and executing AMG’s growth strategy. Mr. Wojcik joined the Company in 2019, serving as Chief Financial Officer from 2019 through 2024, and was named Chief Operating Officer in 2024. He will continue to report to Mr. Horgen. “Since Tom joined 6 years ago, AMG has evolved meaningfully as we have focused on expanding our participation in secular growth...

The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 – 17.00 CEST(Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets Day.The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session.The purpose of the event is to give institutional investors and financial analysts an introduction to the new 5-year strategy for the company, as well as to provide the opportunity to meet with the broader Management team.The day will start with a plenary session, covering the introduction of the new Group strategy, a financial update, and the strategy for the Chronic Care businesses. In the afternoon, participants will...

MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) provides further details on the agenda for the Company’s Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET. This education session will focus on the growth opportunities across Telix’s commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals. The following key opinion leaders will provide their perspectives on the clinical utility and opportunity for Telix’s theranostic candidates.Prostate cancer therapy (TLX591): Oliver Sartor, MD, is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since...